

DMD #85977

TITLE PAGE

**PHARMACOKINETIC INTERACTION BETWEEN NALOXONE AND NALTREXONE
FOLLOWING INTRANASAL ADMINISTRATION TO HEALTHY SUBJECTS**

Philip Krieter, Ph.D., C. Nora Chiang, Ph.D., Shwe Gyaw, M.D., Phil Skolnick, Ph.D., D.Sc.
(hon.), and Rebekah Snyder, B.S.

From: National Institutes of Health National Institute on Drug Abuse, Bethesda, MD
(P.K., C.N.C., S.G., P.S) and Sekisui XenoTech, LLC (R.S.)

Disclosures: P.K. and S.G. are employees of the National Institutes of Health (NIH). C.N.C. is a former employee of NIH. P.S. is an employee of Opiant Pharmaceuticals; he was employed by the NIH when this study was designed and executed. R.S. is an employee of Sekisui XenoTech LLC. None of the authors have any disclosures.

DMD #85977

RUNNING TITLE

PK of Naloxone and Naltrexone with Intranasal Administration

Corresponding Author: Philip A. Krieter
6001 Executive Boulevard
Bethesda, MD 20892
Telephone: 301-827-5930
Fax: 301-443-2599
e-mail: philip.krieter@nih.gov

Number of Text Pages: 19

Number of Tables: 7

Number of Figures: 3

Number of References: 42

Number of Words in Abstract: 248

Number of Words in Introduction: 485

Number of Words in Discussion: 1433

Non-standard abbreviations: AE, adverse event, $AUC_{0-\infty}$, area under the concentration time curve from time zero to infinity; BMI, body mass index; bpm, beats per minute; CI, confidence interval; CL/F, apparent clearance; C_{max} , observed maximum plasma concentration; DDM, dodecyl maltopyranoside; D-PBS, phosphate-buffered saline containing 0.2% bovine serum albumin; HBSS, Hank's balanced salt solution; HPLC, high performance liquid chromatography; IN, intranasal; LC-MS/MS, liquid chromatography with tandem mass spectrometry; mmHg,

DMD #85977

millimeters mercury; MAD, mucosal atomization device; m/z , mass/charge ratio; OCT1, organic cation transporter 1 (SLC22A1); OCT2, organic cation transporter 2 (SLC22A2); OCT3, organic cation transporter 3 (SLC22A3); OCTN1, organic cation/carnitine transporter 1 (SLC22A4); OCTN2, organic cation/carnitine transporter 2 (SLC22A5); P-gp, P-glycoprotein; PK, pharmacokinetics; rpm, respirations per minute; TEA, triethylamine; Trt, treatment; λ_z , elimination phase rate constant.

DMD #85977

ABSTRACT

Naloxone, a mu opioid receptor antagonist, is administered intranasally to reverse an opioid overdose but its short half-life may necessitate subsequent doses. The addition of naltrexone, another mu receptor antagonist which has a reported half-life of 3½ hours, may extend the available time to receive medical treatment. In a Phase 1 pharmacokinetic study, healthy adults were administered naloxone and naltrexone intranasally separately and in combination. When administered with naloxone, C_{\max} of naltrexone decreased 62% and $AUC_{0-\infty}$ decreased 38% compared to when it was given separately; lower concentrations of naltrexone were observed as early as 5 minutes post-dose. In contrast, C_{\max} and $AUC_{0-\infty}$ of naloxone decreased only 18% and 16%, respectively, when given with naltrexone. This apparent interaction was investigated further to determine if naloxone and naltrexone shared a transporter. Neither compound was a substrate for OCT1, OCT2, OCT3, OCTN1, or OCTN2. There was no evidence of the involvement of a transmembrane transporter when they were tested separately or in combination at concentrations of 10 and 500 μM using MDCKII cell monolayers at pH 7.4. The efflux ratios of naloxone and naltrexone increased to 6 or greater when the apical solution was pH 5.5, the approximate pH of the nasal cavity; there was no apparent interaction when the 2 were co-incubated. The importance of understanding how opioid antagonists are absorbed by the nasal epithelium is magnified by the rise in overdose deaths attributed to long-lived synthetic opioids and the realization that better strategies are needed to treat opioid overdoses.

DMD #85977

INTRODUCTION

Opioid overdose in the United States has led to 750,000 emergency department visits and more than 49,000 opioid-related deaths in 2017 (NIDA, 2018). The use of the antagonist naloxone (17-allyl-4,5 α -epoxy-3,14-dihydroxymorphinan-6-one HCl) has been endorsed by multiple government agencies in order to limit opioid-induced fatalities (Surgeon General's Advisory on Naloxone and Opioid Overdose, 2018). Improvised naloxone kits for intranasal (IN) administration have been promoted for use by non-medical personnel and the general public to counteract opioid overdoses (Carpenter et al., 2016), but approximately half of subjects in a human use study could not assemble and use the device without proper training (Edwards et al., 2015). In 2015, the U.S. Food and Drug Administration (FDA) approved Narcan[®], an IN device that delivers 4 mg naloxone in a volume of 0.1 mL. Ninety percent of subjects could use it correctly without any training; it also produces plasma concentrations as rapidly as an intramuscular (IM) injection (Krieter et al., 2016). Due to its short half-life, naloxone may be effective for 1 hour or less, and the person could relapse into respiratory depression, depending on the quantity and nature of the opioid ingested (Li et al., 2018), before trained medical personnel could respond.

Naltrexone [17-(cyclopropylmethyl)-4,5 α -epoxy- 3,14-dihydroxymorphinan-6-one], a mu opioid receptor antagonist, has a reported half-life of approximately 3½ hours (Yuen et al., 1999) and has a 5-fold higher affinity for the receptor compared to naloxone (Cassel et al., 2005). While the duration of occupancy of naloxone on the mu receptor has a half-life of 2 hours (Kim et al., 1997), naltrexone has a half-life of duration of 72 hours (Lee et al., 1988). This is longer than the plasma half-life of naltrexone and its major metabolite 6 β -naltrexol (Meyer et al., 1984),

DMD #85977

suggesting it remains on the receptor longer than indicated by the plasma concentrations.

Combining it with naloxone may increase the window for response to an opioid overdose.

An initial study demonstrated that naltrexone can be absorbed after nasal administration of 2 mg in 1 mL of water; C_{\max} was 3.86 ng/mL at 0.38 hour (Brown et al., 2014). When a crushed extended-release oxycodone tablet containing 3.6 mg naltrexone was administered intranasally, the maximum concentration of the antagonist was 4.4 ng/mL at 0.3 hour (Setnik et al., 2015).

While naltrexone is indicated for the prevention of relapse to opioid dependence, it has not been evaluated for the reversal of an opioid overdose. A pilot study was conducted to assess the feasibility of combining naltrexone with naloxone as an IN formulation to lengthen the time for the reversal of opioid-induced respiratory depression in emergency situations. The results demonstrate reductions in plasma concentrations when the 2 drugs were combined relative to when they were given separately; the reduction in naltrexone concentrations was more pronounced than for naloxone. *In vitro* studies were conducted to determine the nature of the interaction. This report details the results from both the clinical and *in vitro* studies.

MATERIALS AND METHODS

Pharmacokinetic Study

Study Participants. The clinical study was conducted by Vince & Associates Clinical Research (VACR, Overland Park, KS). The study was approved by the MidLands Independent Review Board (Overland Park, KS); all subjects gave written informed consent before participation. The study was carried out in accordance with the International Conference on Harmonization for Good Clinical Practices Guidelines (1996). The study was registered on ClinicalTrials.gov as NCT03851731.

Healthy male and female volunteers aged 18-55 years, with body mass index (BMI) 18-30 kg/m², participated in the PK study. Participants were currently not taking either prescription or over-the-counter medications, and nonsmokers or those who smoked 20 or fewer cigarettes per day were enrolled. Screening procedures conducted within 21 days of study initiation included the following: medical history, physical examination, evidence of nasal irritation, 12-lead electrocardiogram (ECG), complete blood count, clinical chemistry, coagulation markers, hepatitis and human immunodeficiency screening, urinalysis, and urine drug screen. Female participants were tested for pregnancy at screening and admission to the clinic. Participants were excluded if they had either abnormal nasal anatomy or symptoms (eg., runny nose, nasal polyps), an upper respiratory tract infection, used opioid analgesics for pain relief within the previous 14 days, or in the judgment of the investigator, had significant acute or chronic medical conditions. Participants were required to abstain from grapefruit juice and alcohol 72 hours prior to admission to the end of the last blood draw of the study. On days of dosing, a participant's vital signs were required to be within the acceptable range before receiving naloxone, defined as: systolic blood pressure > 90 mmHg and ≤ 140 mmHg; diastolic blood pressure > 55 mmHg and

DMD #85977

≤ 90 mmHg, resting heart rate > 40 beats per minute (bpm) and ≤ 100 bpm, and respiratory rate > 8 respirations per minute (rpm) and ≤ 20 rpm.

Study Design. This was an inpatient, double-blind, randomized, 3-period, 3-treatment, 6-sequence, crossover study. Participants were randomly assigned to 1 of 6 possible sequences. On the day after clinic admission, participants were administered the study drugs in randomized order with a 4-day washout period between doses. Participants remained in the clinic for 13 days until all 3 treatments were administered; they received a follow-up phone call 3 to 5 days after discharge. They fasted from midnight before each dosing day until 1 hour after dose administration. Participants refrained from smoking and caffeine-containing drinks for 1 hour before until 2 hours after dosing. They received 1 of the following 3 treatments in 1 nostril:

- A. 2 mg naltrexone IN (one 0.1 mL spray of a 20 mg/mL formulation)
- B. 4 mg naloxone IN (one 0.1 mL spray of a 40 mg/mL formulation)
- C. 2 mg naltrexone and 4 mg naloxone IN (one 0.1 mL spray of the 20 mg/mL naltrexone plus 40 mg/mL naloxone formulation)

The study drugs were administered in the supine position, and subjects remained in this position for approximately 1 hour after dosing. Participants were instructed not to breathe when the drug was administered to simulate an opioid overdose with a patient in respiratory arrest. Twelve-lead ECGs were collected pre-dose and at 1 and 6 hours post-dose. Venous blood samples (4 mL) were collected for the analyses of plasma naloxone and naltrexone concentrations at pre-dose and 2.5, 5, 10, 15, 20, 30, 45, 60 minutes and 2, 3, 4, 6, 8, 12, 24, 30, 36, 48, 60, and 72 hours post-dose using Vacutainer[®] tubes containing sodium heparin. The plasma was stored at $< -60^{\circ}\text{C}$ until analyzed.

DMD #85977

Study Drugs. Naltrexone HCl and naloxone HCl powders were purchased from Mallinckrodt, Inc. (St. Louis, MO) and were current Good Manufacturing Practices grade. The formulations were made by the pharmacists at VACR; sterile water for injection was the vehicle for both compounds. The study drugs were administered using a LMA mucosal atomization device (Teleflex Medical Europe Ltd., Athlone, Ireland) and a 1-mL disposable syringe. The syringes and devices were weighed before and after dose administration. Based on the dose analysis and weight of the dose administered, the mean milligrams \pm S.D. administered were the following: Treatment A, 2.24 ± 0.03 mg naltrexone HCl; Treatment B, 4.58 ± 0.05 mg naloxone HCl; Treatment C, 2.27 ± 0.07 mg naltrexone HCl and 4.62 ± 0.15 mg naloxone HCl.

Analytical Methods. Plasma naloxone concentrations were assayed as described previously (Krieter et al., 2016); the lower limit of quantitation was 0.01 ng/mL. The interday precision of the calibration curves and quality control samples ranged from 3.22 to 9.05% and the accuracy ranged between -3.14 and 5.33% during the analysis of the samples.

Plasma naltrexone and 6 β -naltrexol concentrations were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay by Xenobiotic Laboratories (Plainsboro, NJ). Plasma samples (0.15 mL) were mixed with 0.1 mL of 1% formic acid in water and 0.05 mL of acetonitrile:water (2:8) containing the internal standards (0.5 ng naltrexone-d₃ and 0.25 ng 6 β -naltrexol-d₃) and added to individual wells of a preconditioned 96-well plate. The plate was washed sequentially with 1% formic acid in water, water, methanol:water (1:1), and methanol. The analytes were eluted using 4% ammonium hydroxide in methanol. After evaporation, the residue was dissolved in 0.15 mL methanol:0.1% formic acid (8:92) and submitted to LC-MS/MS analysis. The AB MDS Sciex API-5000 LC-MS/MS system (Framingham, MA) with atmospheric pressure chemical ionization source was operated

DMD #85977

in the positive ion detection mode. The mobile phase consisted of a gradient from 93% mobile phase A (10 mM ammonium formate, pH 4.0)/7% mobile phase B (acetonitrile: methanol, 2:8) to 80% mobile phase A/20% mobile phase B over 1.7 minutes with a flow rate of 0.5 mL/minute through a 2.1 x 50 mm Kinetex EVO C18 2.6 μ m column (Phenomenex, Torrance, CA).

Naltrexone eluted at approximately 1.45 minutes; ions monitored were m/z 342.2 and 324.2 for naltrexone and 345.2 and 327.3 for its internal standard. 6 β -Naltrexol eluted at approximately 1.60 minutes; ions monitored were m/z 344.2 and 326.2 for 6 β -naltrexol and 347.1 and 329.3 for its internal standard. The interday precision of the calibration curves and quality control samples for naltrexone ranged from 2.92 to 7.87%, and the accuracy ranged between -3.50 and 0.75% during the analysis of the samples. The interday precision of the calibration curves and quality control samples of 6 β -naltrexol ranged from 2.89 to 7.38%, and the accuracy ranged between -7.13 and 2.00% during the analysis of the samples. The lower limit of quantification for both naltrexone and 6 β -naltrexol was 0.02 ng/mL.

Data Analyses. The safety population included all subjects who received at least 1 intranasal dose; the PK population included all participants who received at least 1 dose with sufficient data to calculate meaningful pharmacokinetic parameters. Pharmacokinetic parameters were calculated using standard noncompartmental methods and a validated installation of WinNonlin[®] Phoenix, version 6.3 (Cetera, Princeton, NJ). Values of peak plasma concentrations (C_{max}) and the time to reach C_{max} (T_{max}) were the observed values obtained directly from the concentration-time data. The terminal elimination half-life ($t_{1/2}$) was estimated by linear regression analysis. The area under the concentration time curve from time zero to the last quantifiable concentration (AUC_{0-t}) was determined by the linear up/log down trapezoidal method and extrapolated to infinity (AUC_{0-inf}) by adding the value of the last quantifiable concentration divided by the

DMD #85977

terminal rate constant (λ_z). Since AUC_{extrap} was less than 20% for all participants, only $AUC_{0-\text{inf}}$ is reported. The apparent total body clearance (CL/F) was calculated as the dose divided by $AUC_{0-\text{inf}}$. Within an ANOVA framework, comparisons of ln-transformed PK parameters were performed using a mixed effects model where sequence, period, and treatment were the independent factors. The 90% confidence intervals (CI) for the ratio of the geometric least squares means of C_{max} and $AUC_{0-\text{inf}}$ were constructed for comparison of the 2 drugs administered in combination versus separately. The 90% CIs were obtained by exponentiation of the 90% CIs for the differences between the least squares means based upon an ln scale. All analyses of demographic and safety data were performed using SAS[®] statistical software, version 9.3 (SAS Institute, Inc., Cary, NC).

***In Vitro* Transporter Studies**

Methods. Transporter studies with OCT1, OCT2, and OCT3 were conducted using human embryonic kidney cells (HEK293) cells (ATCC, Manassas, VA) that had been transfected with vectors containing human transporter cDNA; control cells were transfected with the vector only. The culture medium was Dulbecco's modified eagle medium supplemented with 8.9% fetal bovine serum (FBS), 0.89% antibiotic, and 1.79 mM L-glutamine. The incubation medium for the HEK293 cells was Hank's balanced salt solution containing 10 mM HEPES, pH 7.4 (HBSS). OCTN1 and OCTN2 transporter studies used S2 cells established by culturing microdissected S2 segment derived from transgenic mice harboring the temperature-sensitive simian virus 40 large T-antigen gene. Cells were transfected with vectors containing the human transporter cDNA. Control cells for all 5 transporters contained only the vector cDNA. The culture medium for the S2 cells was RITC80-7 supplemented with 4.7% FBS, 9.3 $\mu\text{g}/\text{mL}$ epidermal growth factor, 0.08 units insulin/mL, and 9.5 mg/L transferrin. Phosphate-buffered saline (PBS) containing 0.2%

DMD #85977

bovine serum albumin, pH 7.4 (D-PBS) was used as the incubation medium for the S2 cells. All cells were cultured with 5% CO₂ and 95% relative humidity at 33°C (S2 cells) or 37°C (HEK293 cells).

The medium was removed by aspiration, and cells were rinsed with either 1 mL of HBSS or D-PBS; this was replaced with medium containing the control inhibitor or solvent control, and the cells were preincubated. After preincubation, it was removed and replaced with 0.3 mL buffer containing either the test article or the positive control. The final concentration of naloxone and naltrexone was 1 μM in 0.2% dimethyl sulfoxide, the solvent for the test articles and controls. Cells were incubated for either 2, 5, 10, or 20 minutes at 37°C, at which time the solutions were removed. Positive controls were 10 μM [¹⁴C]metformin (OCT1 and OCT2), 5 μM [¹⁴C]triethylamine (OCT3 and OCTN1), and 0.03 μM [³H]carnitine (OCTN2). All incubations were done in triplicate. HEK293 cells were washed 1 time with 1 mL of ice-cold D-PBS and twice with 1 mL of ice-cold PBS; S2 cells were washed 3 times with ice-cold D-PBS. After removal of the medium, 0.5 mL of purified water was added to each well to lyse the cells, and samples were collected for analysis of naloxone and naltrexone. They were analyzed by LC-MS/MS. Samples were mixed with 20 μL water with the internal standard (nalmeffene). An AB Sciex API-4000 mass spectrometer (Framingham, MA) was operated in the positive mode with an Acquity UPLC BEH C18 analytical column (2.1 x 50 mm, 1.7 μm). The mobile phase consisted of a gradient from 95% mobile phase A (10 mM ammonium acetate)/5% mobile phase B (10 mM ammonium acetate in acetonitrile with 0.1% ammonium hydroxide) to 10% mobile phase A/90% mobile phase B in 2 minutes. The flow rate was 0.5 mL/minute. The ions monitored were *m/z* 328.2 and 310.0 for naloxone, *m/z* 342.2 and 324.1 for naltrexone, and *m/z* 340.3 and 322.3 for the internal standard. Concentrations were calculated as the area of the curve

DMD #85977

compared to that of the internal standard using known concentrations of naloxone and naltrexone. For the positive controls, a 0.3 mL aliquot of the cell lysate was mixed with 5 mL of scintillation cocktail, and radioactivity was measured by liquid scintillation counting. Samples were collected for protein content using the BCA-protein assay (Thermo Fisher Scientific, Waltham, MA). The uptake amount and cleared volume of naloxone and naltrexone were calculated as follows:

Uptake amount into cells (pmol/well) = pmol in cell lysate x 500 μ L/1000 μ L

Cleared volume (μ L/mg protein) = $\frac{\text{uptake amount into cells (pmol/well)}}{\text{mg protein/well} \times \text{initial concentration (pmol/\mu L)}}$

For positive controls, dpm were substituted for pmol in the above equation.

Transport studies were conducted also using wild-type Madin-Darby canine kidney cells (MDCKII) that had been transfected with vectors containing human transporter cDNA (Netherlands Cancer Institute, Amsterdam, Netherlands). Cells were plated and maintained on 24-well transwell plates for 3 to 5 days prior to the experiment. Culture medium was removed and incubation medium (Hank's balanced salt solution supplemented with 25 mM HEPES and 25 mM glucose) was added to the cells. The pH of the basolateral buffer was 7.4 and that of the apical buffer was either pH 7.4 or 5.5. Approximately 10 minutes after incubation medium was added, the transepithelial electrical resistance (TEER) was recorded and cells were preincubated at 37°C for 30-60 minutes. After preincubation, the medium containing naloxone, naltrexone, or control compounds ($[^3\text{H}]$ mannitol and $[^{14}\text{C}]$ caffeine) was added to the donor chamber. Samples were collected from the receiver side at 15, 60, and 120 minutes and replaced by 0.1 mL of incubation medium. TEER was also measured at the end of the incubation to determine if the cells were still confluent. Samples were mixed with 25 μ L of methanol:water (1:1 v/v) and

DMD #85977

75 μL of the internal standard (hydroxybupropion- d_6) in methanol:water (1:1 v/v). They were analyzed by LC-MS/MS using an AB Sciex API-5500 mass spectrometer (Framingham, MA) as described above except the gradient changed from 70% mobile phase A/30% mobile phase B to 5% mobile phase A/95% mobile phase B over 3 minutes. Ions for the internal standard were monitored at m/z 262.0 and 244.0. Concentrations of radioactivity were determined as detailed above.

The apparent permeability (P_{app}) was calculated as:

$$\frac{dQ}{dT} \times \frac{1}{A_0 \times C_0}$$

where dQ is the amount of test drug transported in pmol, dT is the incubation time in seconds, A_0 is the surface area of the membrane in cm^2 , and C_0 is the initial concentration of the test drug in the donor chamber in pmol/cm^3 . The efflux ratio (ER) was calculated as P_{app} basal-to-apical / P_{app} apical-to-basal. The sex of the cell lines used in the experiments is unknown.

DMD #85977

RESULTS

Pharmacokinetic Study

Subject Characteristics. All subjects initiating the study (Table 1) received at least 1 dose of naloxone and/or naltrexone; 11 subjects completed the study. One female subject withdrew during the first period due to a moderate headache with mild nausea that occurred 28 hours after administration of 2 mg naltrexone.

Pharmacokinetics. The geometric means of C_{\max} and $AUC_{0-\text{inf}}$ of naloxone following a 4-mg IN dose were 4.30 ng/mL and 8.13 ng·h/mL (Table 2, Figure 1). The values decreased when it was administered in combination with 2 mg naltrexone approximately 18% for C_{\max} and 16% for $AUC_{0-\text{inf}}$ (Table 3). The median T_{\max} value remained unchanged at 30 minutes, and the elimination half-life was also unchanged.

When naloxone was added to the naltrexone IN formulation, C_{\max} decreased from 4.55 to 1.71 ng/mL, a decline of approximately 62% (Table 2, Figure 2), and $AUC_{0-\text{inf}}$ decreased approximately 38%. The median time to C_{\max} increased from 0.33 to 0.75 hour when the combination formulation was administered compared to naltrexone alone. The half-life of naltrexone, though, was unchanged.

The decreased concentration of naltrexone concentrations in Treatment C was evident even at 5 and 10 minutes after dose administration; concentrations were 83-86% lower than when naltrexone was dosed alone. The concentrations of naltrexone continued to be considerably lower even at 6 hours post-dose.

In contrast, there was no change in the pharmacokinetic values of 6 β -naltrexol when naltrexone was administered with or without naloxone (Tables 2 and 3, Figure 3). The 2 formulations were

DMD #85977

bioequivalent for 6 β -naltrexol, based on the 90% confidence intervals of C_{\max} and $AUC_{0-\infty}$ (Table 3).

There were minor differences in the pharmacokinetic parameters between males and females (Table 4). However, the small sample size of this pilot study precludes any definitive conclusions regarding sex-related differences following IN administration of either drug.

Safety. Five subjects experienced at least 1 adverse event (AE) of any grade or attribution that was judged to be related to the test drugs; all were mild in severity. Headache was the single most frequent AE (3 events in each of 3 subjects). There was 1 drug-related incident of mild inflamed mucosa (score of 1) that occurred 24 hours after dosing with 2 mg naltrexone. Vital signs, ECG, and clinical laboratory parameters did not reveal any clinically significant changes after any of the doses.

In Vitro Transporters

The ratios of naloxone and naltrexone uptake by the 5 transporter-expressing cell lines compared to the control cells were all less than 2, indicating that neither compound was a substrate for OCT1, OCT2, OCT3, OCTN1, or OCTN2 (Table 5). Positive controls had ratios of uptake that ranged from 6.4 for OCT3 to 75.4 for OCTN2 and demonstrated inhibition of uptake by their respective inhibitor.

Permeability of naloxone and naltrexone across a polarized cell layer was tested using control MDCKII cells. Concentrations on the donor side were either 10 or 500 μ M. Transporter studies normally use buffers that are pH 7.4 on both the apical and basolateral side. Since the pH of the nasal passage is approximately pH 5.5-6.5, the studies were conducted also with the apical buffer at pH 5.5 while the basolateral buffer remained at pH 7.4.

DMD #85977

When the pH of the buffer was pH 7.4 on both sides, the efflux ratios of both naloxone and naltrexone were less than 2 at concentrations of 10 and 500 μM (Tables 6 and 7). The addition of 50-fold higher concentration of naloxone to both the lower and higher naltrexone donor solution did not reduce the efflux ratio to an appreciable amount. Similar results were observed when the higher concentration of naltrexone was added to the naloxone solutions.

Lowering the pH of the apical buffer to pH 5.5 while maintaining the basolateral at pH 7.4 caused a 3- to 5-fold decrease in P_{app} values of naltrexone in the A-to-B ratio and 2-to 4-fold increase in the efflux direction (Table 6). The efflux ratios increased to between 12.1 to 18.2. Similar results were observed using naloxone (Table 7). P_{app} values changed considerably whether naloxone and naltrexone were tested separately or in combination.

Mean TEER values were above 100 $\text{ohm} \times \text{cm}^2$ both pre- and post-dose for all of the MDCKII studies. The P_{app} values of [^3H]mannitol were in the range of 0.41 to 1.37 $\times 10^{-6}$ cm/sec in the A-to-B and B-to-A direction while they ranged between 15.5 to 53.5 $\times 10^{-6}$ cm/sec for [^{14}C]caffeine for all the incubations.

DMD #85977

DISCUSSION

Delivery of naloxone by the nasal route has been recognized by the medical community and public officials as an effective way to reverse opioid overdoses (Ryan and Dunne, 2018).

However, the short half-life of naloxone and the increased incidence of overdoses linked to synthetic opioids with a longer duration of action may require more than 1 dose to be administered to prevent re-narcotization (Klebacher et al., 2017). Therefore, the addition of a longer-acting opioid antagonist to the naloxone formulation was initially hypothesized as a means to increase the time to obtain proper medical attention.

The large decrease in the nasal absorption of naltrexone in the presence of naloxone was unexpected. It was observed as early as 5 minutes following administration of both opioid antagonists but was far more pronounced for naltrexone. The C_{max} of naltrexone was reduced to 1.7 ng/mL when the drugs were combined, less than 2 ng/mL, which is generally regarded as a concentration that is sufficient to adequately block the effects of opioid agonists (Comer et al, 2006). The combination product of naloxone and naltrexone was not pursued further.

Although the concentration of naltrexone was below the target of 2 ng/mL, direct absorption into the brain via the olfactory nerves that protrude through the cribiform plate in the olfactory epithelium may lead to a higher concentration at the site of action (Illum, 2000). The cerebral spinal fluid/plasma ratio of zidovudine was higher after IN administration compared to an IV infusion at 15 minutes post-dose in rats (Seki et al., 1994). Similar results were observed in the rat using cephalixin (Sakane et al., 1991). The olfactory epithelium, though, accounts for only 3 to 5% of the nasal cavity's total surface area, which may limit its role in the efficient transfer of drugs directly to the CNS (Grassin-Delyle et al., 2012).

DMD #85977

Rabiner et al (2011) hypothesized that 6 β -naltrexol contributed to the long occupancy of the mu-opioid receptor due to its long plasma half-life. Due to this possibility, the FDA draft guidance on new formulations of naltrexone hydrochloride requires the analysis of 6 β -naltrexol (FDA, 2009). This metabolite, while approximately 2-fold less potent than the parent compound on the mu receptor, is 100-fold less potent than naltrexone *in vivo* in non-human primates (Ko et al., 2006) and has no effect on either morphine-induced analgesia or pupil constriction in humans (Yancey-Wrona et al., 2011). Thus, 6 β -naltrexol is peripherally restricted and its involvement in the central nervous system effects of naltrexone, therefore, is minimal.

While naloxone could have been administered using the FDA-approved device with naltrexone delivered using a mucosal atomization device (MAD), the decision was made to use cGMP-grade material for both compounds and MAD for delivering all 3 formulations. Administering both using the MAD eliminated any time lag that would occur if naloxone and naltrexone were administered in sequence. It also eliminated variability due to the use of 2 different delivery devices for naloxone for Treatments B and C and kept the administered volume at 0.1 mL for all 3 phases of the study.

In this pilot study, sterile water was used as the vehicle. The marketed intranasal formulation of naloxone contains benzalkonium chloride, sodium EDTA, NaCl, and HCl for pH-control (FDA, 2015). The results from the pivotal clinical study (Krieter et al., 2016) and a pilot study using sterile water were very similar (results not shown). Since results using water versus saline with a preservative and stabilizer were similar, a simpler vehicle was used in the present study. In addition, Vanky et al (2017) used water for injection with NaCl as their vehicle for naloxone and produced very similar values as those reported in Krieter et al. (2016). The formulation for the marketed naloxone autoinjector consists of saline and HCl for pH-adjustment (FDA, 2016).

DMD #85977

The pharmacokinetic interaction of the 2 compounds, especially the dramatic effect on naltrexone, remains unexplained. Both compounds have pKa values of approximately 8.0 (Wermeling, 2013) and would be predominantly ionized at pH 5.5-6.5, the pH of the nasal epithelium (England et al., 1999). If absorbed passively, there should not be any significant interaction. The early and large effect on naltrexone suggests that they share a transport mechanism.

Human nasal epithelial cells have appreciable levels of OCT3, OCTN1, and OCTN2 with a minor amount of OCT1 (Shao et al., 2013). They also express P-glycoprotein, several members of the multidrug resistance-associated family, organic anion transporters, and peptide transporters (Al-Ghabeish et al., 2015). Neither naloxone nor naltrexone is a substrate for P-glycoprotein (Kanaan et al, 2009; Doan et al, 2002). Naloxone inhibited the transport of the OATP-A substrate deltorphin II into cRNA-injected oocytes, but it was not tested itself using the system (Gao et al., 2000). None of the 5 cation transporters tested in the present study demonstrated activity towards either naloxone or naltrexone.

The concentrations of naloxone and naltrexone tested in the OCT and OCTN assays were in the low micromolar range so that the transporters were not saturated. However, the concentrations of both compounds in the nasal formulation (53 mM naltrexone and 110 mM naloxone) were much higher in order to keep the administered volume at 0.1-0.15 mL (Grassin-Delyle et al., 2012).

Further *in vitro* studies were conducted using MDCKII cells to determine potential interactions between the 2 compounds. The wild type cell line contains canine MDR1, MRP2, MRP4, and OCTN2 (Gartzke and Fricker, 2014). When both the apical and basolateral solutions were at pH 7.4, there was no indication that either compound interacted with a transporter or with each other. Their apparent permeabilities were greater than 20×10^{-6} cm/sec, the same range as

DMD #85977

caffeine. The efflux ratio was less than 2 when their concentrations were 10 and 500 μM . The addition of 500 μM naloxone did not appreciably affect the permeability of naltrexone at either concentration; similar results were demonstrated when naloxone was tested. The permeability constant was similar between naltrexone and naloxone in both the A-to-B and the B-to-A direction.

In additional experiments, the pH of the apical buffer was lowered to 5.5 while the basolateral was maintained at pH 7.4 to mimic the difference in the pH of the 2 sides of the nasal epithelium (England et al., 1999). In contrast to the initial experiments, the permeability constant of naltrexone in the A-to-B direction decreased 3- to 5-fold while it increased 2- to 4-fold in the opposite direction; the efflux ratio was above 12 for all 4 conditions tested. The P_{app} values did not change appreciably when 500 μM naloxone was added to the apical buffer, suggesting that naltrexone and naloxone were not interacting either with a transporter or with each other. Similar changes were measured when naloxone was tested. While there was some variability, P_{app} values were similar between the 2 compounds. The increased efflux ratio may reflect a “trapping” of the ionized form of naltrexone and naloxone, both weak bases, in the acidic milieu of the apical compartment. This trapping phenomenon has been previously described with other drugs in an acidic environment (Kazmi et al., 2013).

Horvath et al. (2006) showed that the permeability of the substrate for OCTN1 and OCTN2, cationic fluorophore 4-[4-(dimethylamino)-styryl]-N-methylpyridinium, decreased when the pH of the apical buffer decreased from pH 7.4 to 5.7. However, these investigators did not measure the P_{app} value in the efflux direction.

In a study subsequent to the present one, the permeability enhancer dodecyl maltopyranoside (DDM), (Maggio and Pillion, 2013) was added to the solution used to dose 4 mg naltrexone by

DMD #85977

intranasal administration (Krieter et al., 2019). Compared to the control solution, the addition of DDM resulted in an almost three-fold increase in the C_{\max} of naltrexone, a 54% increase of $AUC_{0-\infty}$, and a decrease of the median T_{\max} from 30 minutes to 10 minutes. When examined using MDCKII monolayer cultures, the increased exposure corresponded to a decrease in the transepithelial electrical resistance of approximately 50%. Future studies may explore further the mechanism and clinical relevance of this interaction for other opioid antagonists.

The underlying explanation for the interaction between naltrexone and naloxone when they are administered together intranasally is unclear. While drug-drug interactions have been extensively studied following oral and IV dosing (International Transporter Consortium, 2010), few studies have focused on nasal administration. This route of administration has been advocated for an increasing number of drugs (Costantino et al., 2007; Grassin-Delyle et al., 2012). The importance of understanding how opioid antagonists like naloxone and naltrexone are absorbed by the nasal epithelium is magnified by the dramatic rise in overdose deaths attributed to high potency, long-lived synthetic opioids (eg., fentanyl), and the realization that better strategies are needed to treat opioid overdose.

DMD #85977

AUTHORSHIP CONTRIBUTIONS

Participated in research design: Krieter, Chiang, Gyaw, Skolnick, and Snyder.

Conducted clinical study: Vince & Associates Clinical Research.

Bioanalytical analyses: XenoBiotic Laboratories.

Conducted in vitro experiments: Sekisui XenoTech, LLC.

Performed data analysis: Technical Resources International, Inc and Snyder.

Wrote or contributed to the writing of the manuscript: Krieter, Skolnick, Gyaw, and Snyder.

DMD #85977

REFERENCES

- Al-Ghabeish M, Scheetz T, Assem M, and Donavan M 2015 Microarray determination of the expression of drug transporters in humans and animal species used for the investigation of nasal absorption. *Mol Pharmacol* 12:2742-54.
- Brown DC, Montgomery J, and Gertz B, inventors; 3B Pharmaceuticals, Inc., assignee, Intranasal naltrexone. United States patent US 2014/0249172 A1. Sept 4, 2014.
- Carpenter JE, Wong K, Ndje P, and Ezeonyebuchi UI (2016) Opioid overdose and naloxone delivery devices in the community setting. *Am J Pharm Benefits* 8(6):e96-e100.
- Cassel JA, Daubert JD, and DeHaven RN (2005) [³H]Alvimopan binding to the μ opioid receptor: comparative binding kinetics of opioid antagonists. *Eur J Pharmacol* 520: 29-36.
- Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP, Chiang CP, and Hawks RL (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. *Arch Gen Psychiatry* 63: 210-218.
- Costantino HR, Illum L, Brandt G, Johnson PH, and Quay SC (2007) Intranasal delivery: Physicochemical and therapeutic aspects. *Int J Pharm* 337:1-24.
- Doan KMM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serebjit-Sing CJ, Adkinson KK, and Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiated central nervous system (CNS) and non-CNS marketed drugs. *J Pharmacol Exp Ther* 303:1029-1037.
- Edwards ET, Edwards ES, Davis E, Mulcare M, Wiklund M, and Kelley G (2015) Comparative usability study of a novel auto-injector and an intranasal system for naloxone delivery. *Pain Ther* 4:89-105.

DMD #85977

England R, Homer J, Knight L, and Ell S (1999) Nasal pH measurement: a reliable and repeatable parameter. *Clin Otolaryngol Allied Sci.* 24:67-68.

Food and Drug Administration (2016) Evzio[®] (naloxone hydrochloride injection) Auto-injector for intramuscular or subcutaneous use.

<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209862> (last accessed November, 2018).

Food and Drug Administration (2009) Draft guidance on naltrexone hydrochloride.

<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194641.pdf>. (last accessed December, 2018).

Food and Drug Administration (2015) Narcan[®] (naloxone hydrochloride nasal spray)

<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208411> (last accessed November, 2018).

Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, and Meier PJ (2000) Organic anion-transporting polypeptides mediate the transport of opioid peptides across blood-brain barrier. *J Pharmacol Exp Ther* 294:73-79.

Gartzke D and Fricker G (2014) Establishment of optimized MDCK cell lines for reliable efflux transport studies. *J Pharm Sci* 103:1298-1304.

Grassin-Delye S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc L-J, Le Guen M, Fischler M, and Devillier P (2012) Intranasal drug delivery: an efficient and non-invasive route for systemic administration. Focus on opioids. *Pharmacol Ther* 134:366-379.

DMD #85977

Horvath G, Schmid N, Fragoso MA, Schmid A, Conner GE, Salathe M, and Wanner A (2006) Epithelial organic cation transporters ensure pH-dependent drug absorption in the airway *Am J Respir Cell Mol Biol* 36:53-60.

Illum L (2000) Transport of drugs from the nasal cavity to the central nervous system. *Eur J Pharmaceut Sci* 11:1-18.

International Conference on Harmonisation (ICH) (1996) *Consolidated Good Clinical Practice: Guidelines (E6)*.

http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. (last accessed December, 2017)

International Transporter Consortium (2010) Membrane transporters in drug development. *Nature Rev Drug Discovery* 9: 215-236.

Kanaan M, Daali Y, Dayer P, and Desmeules J (2009) P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone. *Fundam Clin Pharmacol* 23:543-54.

Kazmi F, Hensley T, Pope C, Funk RS, Loewen GJ, Buckley DB, and Parkinson A (2013) Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). *Drug Metab Disp* 41:897-905.

Kim S, Wagner HN, Villemagne VL, Kao P-F, Dannals RF, Ravert HT, Hoh T, Dixon RB, and Civelek AC (1997) Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. *J Nucl Med* 38: 1726-1731.

Klebacher R, Harris MI, Ariyaprakai N, Tagore A, Robbins V, Dudley LS, Bauter R, Koneru S, Hill RD, Wasserman E, Shanes A, Merlin MA (2017) Incidence of Naloxone Redosing in the Age of the New Opioid Epidemic. *Prehosp Emerg Care* 21: 682-687.

DMD #85977

Ko HCH, Divin MF, Lee H, Woods JH, and Traynor JR (2006) Differential in vivo potencies of naltrexone and 6 β -naltrexol in the monkey. *J Pharmacol Exp Ther* 316: 772-779.

Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, Aker J, Beck M, and Harris J (2016) Pharmacokinetic properties and human use characteristics of a n FDA-approved intranasal naloxone product for the treatment of opioid overdose. *J Clin Pharmacol* 56:12143-1253.

Krieter P, Gyaw S, Chiang CN, Crystal R, Skolnick P (2019) Enhanced intranasal absorption of naltrexone by dodecyl maltopyranoside: implications for the treatment of opioid overdose. *J Clin Pharmacol* doi: 10.1002/jcph.1384.

Lee M, Wagner H, Tanada S, Frost J, Bice A, and Dannals R (1988) Duration of occupancy of opiate receptors by naltrexone. *J Nucl Med* 29: 1207-1211.

Li K, Marmenian P, Mason J, and Grock A (2018) Narcan or Nar-can't: tips and tricks to safely reversing opioid toxicity. *Ann Emerg Med* 72: 9-11.

Maggio E, Pillion D (2013) High efficiency intranasal drug delivery using Intravail[®] alkylsaccharide absorption enhancer. *Drug Deliv Transl Res.* 3:16-25.

Meyer MC, Straughn AB, Lo M-W, Schary WL, and Whitney CC (1984) Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. *J Clin Psychiatry* 45: 15-19.

National Institute on Drug Abuse. Overdose death rates. <https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates>. (last accessed November, 2018).

Rabiner E, Beaver J, Makwana A, Searle G, Long C, Nathan PJ, Newbould RD, Howard J, Miller SR, Bush MA, Hill S, Reiley R, Passchier J, Gunn RN, Matthews PM, and Bullmore ET (2011) Pharmacological differentiation of opioid receptor antagonists by molecular and

functional imaging of occupancy and food reward-related brain activation in humans. *Mol Psychiat* 16:826-835.

Ryan SA and Dunn RB (2018) Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review. *Pain Manag* 8:231-245.

Sakane T, Akizuki M, Yamashita S, Sezaki H, Nadai T (1994) Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the dissociation of the drug. *J Pharm Pharmacol* 46:378-379.

Seki T, Sato N, Hasegawa T, Kawaguchi T, Juni K. 1994. Nasal absorption of zidovudine and its transport to cerebrospinal fluid in rats. *Biol Pharm Bull* 17:1135-1137.

Setnick B, Bramson C, Bass A, Levy-Cooperman N, Malhotra B, Matschke K, Sommerville KW, Wolfram G, and Geoffroy P (2015) Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse potential study in nondependent recreational opioid users. *J Clin Pharmacol* 55: 1351-1361.

Shao D, Massoud E, Anand U, Parikh A, Cowley E, Clarke D, Agu RU (2013) Organic cation transporters in human nasal primary culture: expression and functional activity. *Ther Deliv* 4:439-451.

Surgeon General's Advisory on Naloxone and Opioid Overdose.

<https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html>

(last accessed November, 2018).

Vanky E, Hellmundt L, Bondesson U, Eksborg S, Lundeberg S (2017) Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. *Acta Anaesth Scand* 61:636-640.

DMD #85977

Wermeling DP (2013) A response to the opioid overdose epidemic: naloxone nasal spray. *Drug Deliv Transl Res* 3:63-74.

Yancey-Wrona J, Dallaire B, Bilsky E, Bath B, Burkart J, Webster L, Magiera D, Yang X, Phelps, and Sadee W (2011) 6 β -Naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. *Pain Med* 12: 1727-1737.

Yuen KH, Peh KK, Billa N (1999) Comparative bioavailability study of a generic naltrexone tablet preparation. *Drug Devel Ind Pharm* 25:353-356.

FOOTNOTE

This work was supported by the National Institutes of Health National Institute on Drug Abuse. [NIDA contracts N01DA-12-8905, N01DA-13-8920, and N01DA-14-8914].

Reprint requests should be sent to:

Philip A. Krieter

NIH/NIDA

6001 Executive Boulevard

Bethesda, MD 20892-9551

philip.krieter@nih.gov

DMD #85977

FIGURE LEGENDS

Figure 1. Mean (SD) Concentrations of Naloxone in Healthy Participants Following Intranasal Administration of 4 mg Naloxone Alone and in Combination with 2 mg Naltrexone.

Upper graph: concentrations to 12 hours post-dose; Lower graph: concentrations to 1 hour post-dose.

Figure 2. Mean (SD) Concentrations of Naltrexone in Healthy Participants Following Intranasal Administration of 2 mg Naltrexone Alone and in Combination with 4 mg Naloxone.

Upper graph: concentrations to 12 hours post-dose; Lower graph: concentrations to 1 hour post-dose.

Figure 3. Mean (SD) Concentrations of 6 β -Naltrexol in Healthy Participants Following Intranasal Administration of 2 mg Naltrexone Alone and in Combination with 4 mg Naloxone.

DMD #85977

Table 1. Pharmacokinetics of Naloxone: Subject Demographics

	All	Male	Female
Number	12	6	6
Mean age, years (range)	36.0 (22.0-48.0)	39.2 (26.0-48.0)	32.8 (22.0-48.0)
Race			
White	4	1	3
Black/African American	8	5	3
Ethnicity			
Hispanic or Latino	1	0	1
Not Hispanic or Latino	11	6	5
Mean Weight, kg (range)	74.7 (49.4-99.2)	82.7 (71.8-99.2)	66.6 (49.4-84.8)
Mean BMI, kg/m ² (range)	25.0 (19.2-29.3)	25.3 (23.6-27.2)	24.6 (19.2-29.3)

BMI, body mass index

Table 2. Geometric Mean Pharmacokinetic Parameters (%CV) of Naloxone, Naltrexone, and 6 β -Naltrexol

Variable ^a (units)	Naloxone		Naltrexone		6 β -Naltrexol	
	Alone	Plus Naltrexone	Alone	Plus Naloxone	Alone	Plus Naloxone
	(Trt B)	(Trt C)	(Trt A)	(Trt C)	(Trt A)	(Trt C)
N	11	11	12	11	12	11
C _{max} (ng/mL)	4.30 (47.5)	3.60 (36.5)	4.55 (80.0)	1.71 (35.1)	2.09 (32.5)	2.09 (26.2)
T _{max} (h)	0.50 (0.25-0.75)	0.50 (0.25-0.75)	0.33 (0.17-1.0)	0.75 (0.25-2.0)	2.00 (0.75-4.0)	2.00 (0.75-3.0)
AUC _{0-inf} (ng·h/mL)	8.13 (38.2)	7.00 (32.5)	9.61 (39.1)	5.88 (25.2) ^b	30.8 (32.7)	28.3 (28.4)
λ_z (h ⁻¹)	0.380 (32.1)	0.355 (43.9)	0.319 (18.2)	0.322 (10.3) ^b	0.0433 (11.6)	0.0430 (24.5)
t _{1/2} (h)	1.83 (32.1)	1.95 (45.7)	2.17 (18.2)	2.15 (10.3) ^b	16.0 (31.6)	16.1 (24.5)
CL/F (L/min)	6.71 (38.2)	7.79 (43.9)	3.12 (39.1)	5.10 (25.2) ^b	NC	NC

Treatment A: 2 mg naltrexone IN; Treatment B: 4 mg naloxone IN; Treatment C: 2 mg naltrexone plus 4 mg naloxone IN

%CV, percent coefficient of variation; AUC_{0-inf}, area under the plasma concentration-time curve from time zero to infinity; CL/F, apparent clearance; C_{max}, maximum plasma concentration; λ_z , terminal phase rate constant; t_{1/2}, terminal phase half-life; T_{max}, time to C_{max}; NC, not calculated.

a: Geometric mean (%CV) for all except median (range) for T_{max}; b: N = 10.

DMD #85977

Table 3. Statistical Summary of Treatment Comparisons

Variable	Analyte	Comparison (Trt C vs Reference)	Geometric Mean Ratio (Trt C/Reference)	90% CI
C_{\max} (ng/mL)	Naloxone	C vs B	81.5	63.6-105
	Naltrexone	C vs A	38.4	25.7-57.3
	6 β -Naltrexol	C vs A	101	92.7-110
$AUC_{0-\infty}$ (ng·h/mL)	Naloxone	C vs B	84.3	70.1-102
	Naltrexone	C vs A	61.6	50.9-74.6
	6 β -Naltrexol	C vs A	94.4	89.3-99.8

$AUC_{0-\infty}$, area under the plasma concentration-time curve from time zero to infinity; C_{\max} , maximum plasma concentration

Treatment A: 2 mg naltrexone IN; Treatment B: 4 mg naloxone IN; Treatment C: 2 mg naltrexone plus 4 mg naloxone IN

Table 4. Geometric Mean Pharmacokinetics Parameters (%CV) of Naltrexone and Naloxone in Female and Male Participants

Variable (Units) ^a	Naloxone (Trt B)		Naloxone (Trt C)		Naltrexone (Trt A)		Naltrexone (Trt C)	
	Female	Male	Female	Male	Female	Male	Female	Male
N	5	6	5	6	6	6	5	6
C _{max} (ng/mL)	4.75 (62.4)	3.96 (36.6)	3.41 (42.6)	3.77 (34.2)	5.45 (50.8)	3.80 (109)	1.71 (43.2)	1.71 (31.6)
T _{max} (h)	0.75 (0.25-0.75)	0.42 (0.27-0.75)	0.50 (0.33-0.50)	0.50 (0.25-0.75)	0.42 (0.17-1.0)	0.33 (0.25-0.75)	1.0 (0.50-2.0)	0.75 (0.25-1.0)
AUC _{0-inf} (ng·h/mL)	8.90 (46.3)	7.55 (32.7)	7.33 (47.9)	6.74 (17.9)	11.9 (19.2)	7.75 (42.6)	7.07(29.7) ^b	5.20 (12.3)
λ _z (h ⁻¹)	0.412 (30.0)	0.355 (34.9)	0.407 (32.6)	0.317 (51.8)	0.309 (24.0)	0.329 (11.6)	0.314 (14.0) ^b	0.327 (8.08)
t _{1/2} (h)	1.68 (30.0)	1.95 (34.9)	1.70 (32.6)	2.19 (51.8)	2.25 (24.0)	2.10 (11.6)	2.21 (14.0) ^b	2.12 (8.08)
CL/F (L/min)	6.13 (46.3)	7.23 (32.7)	7.44 (47.9)	8.10 (17.9)	2.52 (19.2)	3.87 (42.6)	4.25 (29.7) ^b	5.76 (12.3)

Treatment A: 2 mg naltrexone IN; Treatment B: 4 mg naloxone IN; Treatment C: 2 mg naltrexone plus 4 mg naloxone IN

% CV, percent coefficient of variation; AUC_{0-inf}, area under the plasma concentration-time curve from time zero to infinity; CL/F, apparent clearance; C_{max}, maximum plasma concentration; t_{1/2}, terminal phase half-life; λ_z, terminal phase rate constant; T_{max}, time to C_{max}.

a: Geometric mean (%CV) for all except median (range) for T_{max}; b: N = 4.

Table 5. Uptake of Naloxone and Naltrexone into Transport-Expressing and Control Cells

Transporter	Compound	Concentration (μM)	Inhibitor	Incubation Time (min)	Cleared Volume ^a ($\mu\text{L}/\text{mg}$ protein)		Test/Control Ratio
					Control Cells	+ Transporter	
OCT1	Naloxone	1	-	10	31.4 ± 0.4	28.7 ± 1.8	0.9
	Naltrexone	1	-	10	65.7 ± 3.8	70.3 ± 6.6	1.1
	[¹⁴ C]Metformin	10	-	5	0.940 ± 0.113	13.1 ± 0.2	13.9
	[¹⁴ C]Metformin	10	100 μM quinidine	5	0.158 ± 0.023	0.609 ± 0.001	3.9
OCT2	Naloxone	1	-	10	37.1 ± 4.7	37.3 ± 6.2	1.0
	Naltrexone	1	-	10	78.0 ± 11.3	71.0 ± 6.4	0.9
	[¹⁴ C]Metformin	10	-	2	0.609 ± 0.080	46.4 ± 0.2	76.2
	[¹⁴ C]Metformin	10	100 μM quinidine	2	0.240 ± 0.031	0.652 ± 0.225	2.7
OCT3	Naloxone	1	-	20	30.6 ± 4.2	35.9 ± 2.5	1.2
	Naltrexone	1	-	20	88.9 ± 7.5	80.2 ± 5.9	0.9
	[¹⁴ C]TEA	5	-	20	3.29 ± 0.31	20.9 ± 0.6	6.4
	[¹⁴ C]TEA	5	100 μM verapamil	20	0.946 ± 0.143	1.22 ± 0.32	1.3
OCTN1	Naloxone	1	-	10	197 ± 4	134 ± 25	0.7
	Naltrexone	1	-	10	179 ± 24	190 ± 56	1.1

Downloaded from dmd.aspetjournal.org at ASPET Journals on October 22, 2009

DMD #85977

	[¹⁴ C]TEA	5	-	5	0.998 ± 0.259	12.1 ± 1.4	12.1
	[¹⁴ C]TEA	5	100 μM verapamil	5	0.579 ± 0.148	0.877 ± 0.228	1.5
OCTN2	Naloxone	1	-	10	179 ± 16	161 ± 6	0.9
	Naltrexone	1	-	10	209 ± 19	209 ± 46	1.0
	[³ H]Carnitine	0.03	-	2	1.32 ± 0.04	99.5 ± 3.8	75.4
	[³ H]Carnitine	0.03	30 μM verapamil	2	0.953 ± 0.109	31.4 ± 2.2	32.9

a: N = 3, Mean ± SD

Downloaded from dmj.sagepub.com at ASPET Journals on October 22, 2019

DMD #85977

Table 6. Bidirectional Permeability of Naltrexone Across MDCKII cells

Concentrations	P_{app} ($\times 10^{-6}$ cm/sec)		Efflux Ratio
	A to B	B to A	
Apical and Basolateral pH = 7.4			
10 μ M Naltrexone	24.3 (29.9)	36.1 (6.9)	1.49
10 μ M Naltrexone / 500 μ M Naloxone	27.9 (5.0)	33.3 (5.7)	1.19
500 μ M Naltrexone	36.2 (8.2)	39.1 (2.8)	1.08
500 μ M Naltrexone / 500 μ M Naloxone	26.7 (7.1)	41.4 (6.0)	1.55
Apical pH = 5.5 / Basolateral pH = 7.4			
10 μ M Naltrexone	5.13 (1.6)	62.3 (6.1)	12.1
10 μ M Naltrexone / 500 μ M Naloxone	6.92 (24.1)	122 (4.1)	17.6
500 μ M Naltrexone	7.48 (7.0)	136 (2.9)	18.2
500 μ M Naltrexone / 500 μ M Naloxone	7.51 (6.7)	107 (2.8)	14.2

P_{app} , Apparent permeability; Efflux ratio, P_{app} of basolateral to apical direction divided by P_{app} of apical to basolateral direction.

P_{app} values are mean (%CV), n = 3.

^3H -Mannitol P_{app} = 0.49 to 1.37 $\times 10^{-6}$ cm/sec; ^{14}C -caffeine P_{app} = 31.2 to 34.3 $\times 10^{-6}$ cm/sec.

DMD #85977

Table 7. Bidirectional Permeability of Naloxone Across MDCKII cells

Concentrations	P_{app} ($\times 10^{-6}$ cm/sec)		Efflux Ratio
	A to B	B to A	
Apical and Basolateral pH = 7.4			
10 μ M Naloxone	30.6 (5.2)	31.5 (10.8)	1.03
10 μ M Naloxone / 500 μ M Naltrexone	39.6 (10.9)	23.7 (3.8)	0.60
500 μ M Naloxone	25.3 (9.5)	48.3 (3.1)	1.91
500 μ M Naloxone / 500 μ M Naltrexone	19.7 (9.1)	37.3 (0.8)	1.90
Apical pH = 5.5 / Basolateral pH = 7.4			
10 μ M Naloxone	6.48 (25.6)	43.3 (4.6)	6.69
10 μ M Naloxone / 500 μ M Naltrexone	5.83 (8.7)	62.5 (1.1)	10.7
500 μ M Naloxone	3.29 (6.7)	174 (6.3)	52.9
500 μ M Naloxone / 500 μ M Naltrexone	5.08 (4.9)	134 (6.0)	26.3

P_{app} , Apparent permeability; Efflux ratio, P_{app} of basolateral to apical direction divided by P_{app} of apical to basolateral direction.

P_{app} values are mean (%CV), n = 3.

^3H -Mannitol P_{app} = 0.41 to 1.11 $\times 10^{-6}$ cm/sec; ^{14}C -caffeine P_{app} = 15.5 to 53.5 $\times 10^{-6}$ cm/sec.

Figure 1.




Figure 2.




Figure 3.

